EGFR and non-small cell lung carcinoma: In patients with the C797S mutation and loss of the T790M mutation after progression to osimertinib therapy, first-generation EGFR-TKIs (gefitinib and erlotinib) have been reported to be effective in treating NSCLC with the C797S mutation alone [28, 30].